Skip to main content
. 2019 Dec 5;11(3):603–616. doi: 10.1111/jdi.13171

Table 6.

Immunomodulation therapy for patients with type B insulin resistance syndrome

Immunomodulation therapy No. patients
Steroid 12 (40.0%)
Helicobacter pylori eradication therapy 3 (10.0%)
Cyclosporine 2 (6.7%)
Azathioprine 1 (3.3%)
Human immunoglobulin 1 (3.3%)
None 16 (53.3%)